AU2023901744A0 - Cell line 3 selected for therapeutic efficacy and related compositions and methods - Google Patents

Cell line 3 selected for therapeutic efficacy and related compositions and methods

Info

Publication number
AU2023901744A0
AU2023901744A0 AU2023901744A AU2023901744A AU2023901744A0 AU 2023901744 A0 AU2023901744 A0 AU 2023901744A0 AU 2023901744 A AU2023901744 A AU 2023901744A AU 2023901744 A AU2023901744 A AU 2023901744A AU 2023901744 A0 AU2023901744 A0 AU 2023901744A0
Authority
AU
Australia
Prior art keywords
methods
cell line
therapeutic efficacy
related compositions
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023901744A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Magellan Stem Cells Pty Ltd
Original Assignee
Magellan Stem Cells Pty Ltd
Filing date
Publication date
Application filed by Magellan Stem Cells Pty Ltd filed Critical Magellan Stem Cells Pty Ltd
Publication of AU2023901744A0 publication Critical patent/AU2023901744A0/en
Pending legal-status Critical Current

Links

AU2023901744A 2023-06-02 Cell line 3 selected for therapeutic efficacy and related compositions and methods Pending AU2023901744A0 (en)

Publications (1)

Publication Number Publication Date
AU2023901744A0 true AU2023901744A0 (en) 2023-06-22

Family

ID=

Similar Documents

Publication Publication Date Title
EP4003401A4 (en) Compositions and methods comprising protease-activated therapeutic agents
EP4175949A4 (en) Methods and compositions for targeting tregs using ccr8 inhibitors
EP4090752A4 (en) Plakophillin-2 gene therapy methods and compositions
EP4110358A4 (en) Placental tissue compositions and methods
AU2023901743A0 (en) Cell line 2 selected for therapeutic efficacy and related compositions and methods
AU2023901744A0 (en) Cell line 3 selected for therapeutic efficacy and related compositions and methods
AU2022901507A0 (en) Cell line 2 selected for therapeutic efficacy and related compositions and methods
AU2022901509A0 (en) Cell line 3 selected for therapeutic efficacy and related compositions and methods
EP4114176A4 (en) Sterilization compositions and methods for using thereof
AU2021901727A0 (en) Cell line 2 selected for therapeutic efficacy and related compositions and methods
AU2021901728A0 (en) Cell line 3 selected for therapeutic efficacy and related compositions and methods
AU2024901664A0 (en) Cell line 3 selected for therapeutic efficacy and related compositions and methods
AU2024901663A0 (en) Cell line 2 selected for therapeutic efficacy and related compositions and methods
AU2023901742A0 (en) Cell line selected for therapeutic efficacy and related compositions and methods
AU2022901506A0 (en) Cell line selected for therapeutic efficacy and related compositions and methods
AU2024901662A0 (en) Cell line selected for therapeutic efficacy and related compositions and methods
AU2021901726A0 (en) Cell line selected for therapeutic efficacy and related compositions and methods
EP4175978A4 (en) Compositions and methods for treating crp-mediated diseases
EP4136072A4 (en) Compositions and methods for treating pain and/or inflammation
AU2023901412A0 (en) Therapeutic Agents and Compositions and Related Methods
AU2024900070A0 (en) Therapeutic methods and related compositions
EP3941453A4 (en) Therapeutic methods and compositions for treating lymphoma using 6,8-bis-benzylthio-octanoic acid
AU2024900581A0 (en) Therapeutic And Prophylactic Agents and Related Compositions And Methods
AU2022900368A0 (en) Compositions and Methods for Modulating Inflammation 2
AU2022900370A0 (en) Compositions and Methods for Modulating Inflammation 3